Literature DB >> 2363922

T2 glottic cancer. Recurrence, salvage, and survival after definitive radiotherapy.

D Howell-Burke1, L J Peters, H Goepfert, M J Oswald.   

Abstract

The records of all patients with T2, NO squamous cell carcinoma of the true vocal cords treated with definitive radiotherapy at The University of Texas M. D. Anderson Cancer Center between 1970 and 1985 were analyzed to investigate treatment outcome, prognostic factors associated with tumor recurrence, and the potential impact of improved initial treatment on patient survival. There were 114 patients (male to female ratio, 13:1) with a median age of 62 years at presentation. All were treated with external beam irradiation to a modal dose of 70 Gy in 35 fractions over 7 weeks. The median field size was 25 cm2 and no elective treatment to the neck was routinely given. The crude recurrence rate after definitive radiotherapy was 32%. Of the 37 local regional failures, 32 were in the larynx only, 3 in the neck, and 2 in both the larynx and the neck. All patients who had recurrence after radiotherapy underwent salvage procedures, which increased the ultimate control rate above the clavicles to 94%. Overall and disease-specific survival rates at 5 years were 69% and 92%, respectively. Fifty patients died: 7 of laryngeal cancer, 2 of complications of salvage surgery, 13 of unrelated second cancers, and 28 of other intercurrent disease. The prospects for improved survival through more effective initial treatment of this stage of glottic cancer are therefore very limited. Significant complications of radiotherapy occurred in only 4 patients (3.5%), and overall, 74% of patients retained a functional larynx. Analysis of a wide variety of patient-, tumor-, and treatment-related variables failed to identify any statistically significant prognostic factors.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2363922     DOI: 10.1001/archotol.1990.01870070078014

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  9 in total

1.  Hyperfractionated radiotherapy for T2 glottic cancer for preservation of the larynx.

Authors:  Ichiro Tateya; Shigeru Hirano; Hisayoshi Kojima; Koichi Omori; Kazuhiko Shoji; Michihide Mitsumori; Yasushi Nagata; Juichi Ito
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-07-13       Impact factor: 2.503

2.  Prospective analysis of functional swallowing outcome after resection of T2 glottic carcinoma using transoral laser surgery and external vertical hemilaryngectomy.

Authors:  Hani Osama Nasef; Hossam Thabet; Cesare Piazza; Francesca Del Bon; Mohamed Eid; Manal El Banna; Piero Nicolai
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-27       Impact factor: 2.503

3.  Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx.

Authors:  Danielle L Gainor; Emily Marchiano; Emily Bellile; Matthew E Spector; Jeremy M G Taylor; Gregory T Wolf; Norman D Hogikyan; Mark E Prince; Carol R Bradford; Avraham Eisbruch; Francis Worden; Andrew G Shuman
Journal:  Otolaryngol Head Neck Surg       Date:  2017-06-13       Impact factor: 3.497

4.  The "gregorio marañon" hospital experience in the treatment of laryngeal carcinoma.

Authors:  M F Vega; T Martinez; B Scola; E Scola; S F Vega
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  1997-07

5.  Conventional fractionation should not be the standard of care for T2 glottic cancer.

Authors:  Lynne M Dixon; Catriona M Douglas; Shazril Imran Shaukat; Kate Garcez; Lip Wai Lee; Andrew J Sykes; David Thomson; Nicholas J Slevin
Journal:  Radiat Oncol       Date:  2017-11-14       Impact factor: 3.481

6.  Mapping of sentinel lymph node drainage using SPECT/CT to tailor elective nodal irradiation in head and neck cancer patients (SUSPECT-2): a single-center prospective trial.

Authors:  Pieter D de Veij Mestdagh; Willem H Schreuder; Wouter V Vogel; Maarten L Donswijk; Eric van Werkhoven; Jacqueline E van der Wal; Richard Dirven; Baris Karakullukcu; Jan-Jakob Sonke; Michiel W M van den Brekel; Corrie A M Marijnen; Abrahim Al-Mamgani
Journal:  BMC Cancer       Date:  2019-11-14       Impact factor: 4.430

7.  Vocal-cord Only vs. Complete Laryngeal radiation (VOCAL): a randomized multicentric Bayesian phase II trial.

Authors:  Houda Bahig; David I Rosenthal; Félix-Phuc Nguyen-Tan; David C Fuller; Ying Yuan; Katherine A Hutcheson; Apostolos Christopoulos; Anthony C Nichols; Kevin Fung; Olivier Ballivy; Edith Filion; Sweet Ping Ng; Louise Lambert; Jennifer Dorth; Kenneth S Hu; David Palma
Journal:  BMC Cancer       Date:  2021-04-22       Impact factor: 4.430

8.  Assessment of disease-free survival in patients with laryngeal squamous cell carcinoma treated with radiotherapy associated or not with chemotherapy.

Authors:  Helma Maria Chedid; Carlos Neutzling Lehn; Abrão Rapoport; Ali Amar; Sérgio Altino Franzi
Journal:  Braz J Otorhinolaryngol       Date:  2010 Mar-Apr

9.  The role of red cell distribution width in the locoregional recurrence of laryngeal cancer.

Authors:  Gülpembe Bozkurt; Arzu Yasemin Korkut; Pınar Soytaş; Senem Kurt Dizdar; Zeynep Nur Erol
Journal:  Braz J Otorhinolaryngol       Date:  2018-04-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.